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Abstract 
Elucidating the molecular basis of complex human psychiatric disorders is challenging 
due to the multitude of factors that underpin these disorders. Genetic and chromosomal 
changes are two factors that have been suggested to be involved in psychiatric disorders. 
Indeed, numerous risk loci have been identified in autism spectrum disorders (ASD), 
schizophrenia, and related psychiatric disorders. Here, we introduce genetic animal 
models that disturb excitatory-inhibitory (E/I) balance in the brain and animal models 
mirroring human chromosomal abnormalities, both of which may be implicated in ASD 
pathophysiology. In addition, we discuss recent unique translational research using 
rodent models, such as Cntnap2 knockout (KO) mouse, Mecp2 mutant mouse, Pick1 
KO mouse, and NVHL (Neonatal Ventral Hippocampal Lesion) rat. By using these 
models, several types of drugs are administered during the developmental period to see 
the effect on psychotic symptoms and neural activities in adults. The accumulating 
evidence from recent animal studies provides informative intervention strategy as a 
translational research. 
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Introduction 
The pathophysiology of psychiatric disorders is complex. Factors that may contribute to 
the development of psychiatric disease include imbalance in excitatory and inhibitory 
(E/I) transmission and chromosomal changes. The E/I imbalance can be caused by 
modulation of receptors that in turn lead to abnormal activity of glutamatergic neurons 
and γ-aminobutyric acid (GABA)ergic interneurons. Indeed, genes involved in E/I 
transmission are reported to be dysregulated in postmortem brains of patients with 
schizophrenia and Rett Syndrome (RTT)12. Chromosomal abnormalities are another 
factor associated with psychiatric disorders. Copy number variation (CNVs) are 
duplications or deletions of genomic loci, ranging from kilobase (Kb) to megabase (Mb), 
and can pertain to either a single gene or multiple genes3. Autism Spectrum Disorder 
(ASD), schizophrenia, and RTT are diseases attributed to CNVs.  
Uncovering the mechanism whereby specific genetic abnormalities lead to 
psychiatric disease is difficult to do in clinical studies. However, rodent models can be a 
useful tool in understanding the potential role of E/I imbalance and chromosomal 
abnormalities on the development of psychiatric disorders. In addition, rodent models 
permit the systematic testing of therapeutics during different stages of disease onset to 
determine the efficacy of the timing of treatment interventions. This review will focus 
on rodent models of E/I imbalance and CNVs relevant to psychiatric disorders. Rodent 
models suggesting the usefulness of treatment early in disease progression are also 
discussed. 
 
1. Rodent models of Excitatory and Inhibitory (E/I) imbalance 
Patients with ASD and other psychiatric disorders are thought to have E/I imbalance in 
the brain45. ASD patients frequently present with epileptic seizures, with a prevalence 
rate estimated to range between 8 and 25%6. Epileptic seizures may be due to excess 
excitatory neuronal inputs of the cortical circuit, suggesting E/I imbalance in the brains 
of ASD patients7. Indeed, a recent study showed that three-dimensional cultures 
(cortical organoids) derived from individuals with severe idiopathic ASD have normal 
levels of glutamatergic excitatory neurons and increased numbers of GABAergic 
inhibitory neurons8. Also, a functional genetic analysis on patients with schizophrenia 
has uncovered genes involved in glutamatergic and GABAergic neurotransmission, 
suggesting these patients also have E/I imbalance9. In addition, patients with the 
X-linked neurodevelopmental disorder, RTT, have been shown to have hypoexcitability 
in the forebrain, possibly indicating E/I imbalance3. Postmortem brain studies of RTT 
patients have shown a decrease in glutamatergic 
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±-amino-3-hydroxy-5-methylisoxazol-4-propionic acid receptor (AMPAR) and 
N-methyl-D-aspartate receptor (NMDAR) densities in the putamen and a decrease in 
GABA receptors in the caudate10. These studies demonstrate the heterogeneity of E/I 
imbalance associated with mental illness. However, the mechanism of E/I imbalance 
induced psychiatric symptoms is difficult to tease this apart with human studies. 
Therefore, rodent models are useful tools in elucidating the behavioral, molecular, 
cellular, and electrophysiological outcomes of E/I imbalance associated with psychiatric 
diseases (Table 1).  
Rodent models with E/I imbalance exhibit phenotypes reminiscent of patients 
with ASD and schizophrenia. For example, Yizhar et al. utilized optogenetics to elevate 
excitatory neurons in the medial prefrontal cortex (mPFC) of mice. These mice 
displayed social deficits and an increase in electroencephalogram frequency as 
compared to controls, reminiscent of deficits observed in patients with ASD and 
schizophrenia11. Another mouse model is the insulin receptor substrate protein 53 kDa 
(IRSp53) knockout (KO) mouse. IRSp53 is an excitatory synaptic scaffolding molecule 
detected throughout the brain12. IRSp53 KO mice showed enhanced hippocampal 
NMDAR function and impaired social interaction, a behavior observed in patients with 
ASD as well as the optogenetics mouse model of elevated mPFC excitatory neurons. 
Interestingly, administration of the NMDAR antagonist memantine or the selective 
metabotropic glutamate receptor5 (mGluR5) antagonist 2-methyl-6-(phenylethynyl) 
pyridine (MPEP) was able to recover the social deficits observed in IRSp53 KO mice13. 
Testing these drugs for the ablation of social deficits in other mouse models would be an 
interesting step towards efficacy in treating humans. While the optogenetics and IRSp53 
KO rodent models increase the E/I ratio in the brain by modifying excitatory neurons, 
other rodent models increase the E/I ratio by modulating inhibitory neurons. Brown et 
al. increased the E/I ratio in the neocortex and dentate gyrus of mice by knocking down 
Gad1 in these brain regions. Gad1 encodes the 67-kDa isoform of glutamic acid 
decarboxylase (Gad67) and is important for inhibitory neurons. Gad1 knock-down mice 
exhibited a decrease in inhibitory parvalbumin (PV) -expressing interneurons and 
displayed sensorimotor gating deficits, increased novelty-seeking, and reduced fear 
extinction14. Another group ablated metabotropic glutamate receptor 5 (mGluR5) on 
PV-expressing interneurons, which resulted in reduced numbers of PV neurons, 
decreased inhibitory currents, and behavioral abnormalities in mice. These mice 
exhibited increased repetitive behavior, impaired recognition memory, and sensory 
motor gating abnormalities15. Treatment of conditional mGluR5 KO (in forebrain 
glutamatergic neurons) mice with MPEP decreased mPFC firing of GABAergic neurons 
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and increased firing of glutamatergic neurons16. These results elucidate a possible 
anti-psychotic action of MPEP and suggest that mGluR5 directly regulates E/I balance 
by dominantly regulating inhibitory neuronal input onto glutamatergic neurons. While 
memantine recovers deficits in a genetic KO, another NMDAR antagonist, ketamine, 
has also been assessed by Patrizi et al. They reported that chronic administration of 
ketamine from either postnatal day (P)15 or P30 to P55 increased neuronal activity, 
lifespan, respiratory function, and visual acuity of Mecp2-null (KO) mice. The authors 
confirmed that low-dose chronic ketamine administration (8 mg/kg) is rapidly detected 
in the brain without any adverse side effects. Intriguingly, the time points chosen for the 
start of ketamine administration correlate with when PV cortical circuits are altered 
(P15) and the onset of RTT phenotypes (P30). Since the spiking activities of cortical 
excitatory neurons are tightly regulated by PV-positive inhibitory neurons17, it is 
possible that ketamine preferentially modulates NMDAR on PV-positive cells, leading 
to disinhibition of pyramidal cells and thus renormalizing E/I balance in the cortex of 
the Mecp2 KO mouse model of RTT. The pharmacological studies discussed in this 
section support previous findings that E/I imbalance in the mPFC affects sociability11, 
and show that pharmacological intervention of receptors such as mGluR5 or NMDAR, 
may be effective against psycho-social deficits. 
 
Table 1. Representative animal models of E/I imbalance 
Animal model E/I ratio Phenotypes Rescue Reference 
Optogenetic 
control 
Increase in 
mPFC 
Social deficits, high 
frequency 
electroencephalogram 
(30-80Hz) 
Optogenetic Yizar et al. 
(2011)11 
Gad1 
knockdown 
Increase Sensorimotor gating 
deficits, increased 
novelty-seeking, and 
reduced fear 
extinction 
- Brown et al. 
(2015)14 
Postnatal 
ablation of 
mGluR5 from 
PV-expressing 
interneuron 
Increase Impaired recognition 
memory, increased 
repetitive behaviors, 
and sensory motor 
gating abnormalities 
- Barnes et al. 
(2015)15 
IRSp53 KO Increase Social deficits Memantin Chung et al. 
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(NMDAR 
antagonist) 
MPEP 
(selective 
antagonist for 
the 
metabotropic 
glutamate 
receptor 
subtype 
mGluR5) 
(2015)13 
mGluR5 
KOknockout 
in GABArgic 
neurons 
Increase Antidepressant-like 
behavior 
- Lee et al. 
(2015)16 
mGluR5 KO 
in 
glutamatergic 
neurons 
Decrease Depression-like 
behavior 
MPEP Lee et al. 
(2015)16 
Mecp2 KO Decrease Several neurological 
and psychological 
phenotypes18 
Ketamine 
(NMDAR 
antagonist) 
Patrizi et al. 
(2016)19 
 
2. Rodent models of Copy Number Variations 
CNV is defined as deletion or duplication of a genomic locus larger than 1 Kb in size. 
Some CNVs encompass dozens of genes that may include coding gene(s) or genes in 
regulatory regions20 such as the promoter, enhancer, and silencer, while others pertain to 
only a single gene. Available mouse models of CNVs include 7q11.23 (deletion)21, 
15q11-13 (duplication)22, 15q13.3 (deletion)2324, 16p11.2 (deletion and duplication)25, 
17p11.2 (deletion and duplication)26, 22q11.2 (deletion)27, and MECP2 (deletion and 
duplication). These mice are known to display behavioral and brain abnormalities 
paralleling what has been frequently reported in patients28. In this review, we focus on 
CNV mouse models of 15q11-13, 22q11.2, and MECP2.  
 
2.1. 15q11-13 duplication  
A duplication in 15q11-13 is one of the most prevalent chromosomal abnormalities in 
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ASD. This region is syntenic to mouse chromosome 7qB5-qC. The 15q11-13 
chromosomal duplication confers >85% risk of developing ASD, and is found in 1-3% 
of individuals with ASD29. Mice with paternally inherited 6 Mb 15q11-13 duplication (6 
Mb patDp/+) displayed social deficits, behavioral inflexibility, and abnormal ultrasonic 
vocalization (USV), which are typical autistic behavioral phenotypes in rodents. These 
behaviors were not present in mice with a maternally inherited duplication (matDp/+)22. 
In addition to behavioral abnormalities, 6 Mb patDp/+ mice had decreased serotonin 
levels in the developing brain30 and displayed late-onset obesity31, both of which 
resemble what is observed in patients with paternally inherited 15q11-13 duplication32. 
Recently, in order to identify a causal gene of obesity, Kishimoto et al. generated a new 
mouse model with a 3 Mb 15q11-13 paternal duplication (3 Mb patDp/+)31. 
Transcriptome analysis on these mice revealed an up-regulation in the gene secreted 
frizzled-related protein 5 (Sfrp5). Sfrp5 induces adipocyte differentiation and increases 
adipocytes during obesity. This gene may therefore be a possible target for combating or 
preventing obesity accompanied by autistic symptoms, but it may not be effective 
against cognitive dysfunction or social deficits. 
Another hallmark of ASD and some behavioral changes such as deregulation of 
motor coordination and learning33, is cerebellar dysfunction. 6 Mb patDp/+ mice 
exhibited impaired cerebellum-dependent motor learning and coordination, but normal 
cerebellar morphology223435. This is consistent with a magnetic resonance imaging 
(MRI) study in patDp/+ mice that revealed regional difference existing in the dentate 
gyrus, medial striatum, and dorsal raphe nucleus, but not in the cerebellar cortex363738. 
In addition, patDp/+ mice showed impaired long-term depression (LTD) at cerebellar 
parallel fiber-Purkinje cell synapses39, which may reflect a cellular mechanism 
underlying motor learning impairment. Since the cerebellum is likely involved in motor 
and non-motor aspects of ASD phenotypes33, cerebellar abnormalities may be involved 
in a portion of the ASD pathophysiology. 
 
2.2. 22q11.2 deletion  
The 22q11.2 deletion, a region syntenic to mouse chromosome 16qA3, is also known as 
DiGeorge syndrome and velo-cardio-facial syndrome. It is one of the most common 
chromosomal abnormalities, occurring in 1 out of every 4,000 live births40. Most cases 
(90%) are of a 3 Mb microdeletion on the long arm of chromosome 22, but a 1.5 Mb 
microdeletion is also common and has been reported in 8% of cases41. The 22q11.2 
microdeletion has been associated with congenital heart defects (CHD), palatal 
anomalies, hypoparathyroidism, hypocalcemia, facial dysmorphisms, and learning 
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disabilities. Additionaly, this chromosomal deletion has been strongly associated with 
schizophrenia and other mental illnesses such as anxiety disorders, mood disorders, 
ASD, and attention deficit hyperactivity disorder (ADHD)42. 
 In recent years, through genetically modified mutant mice that carry multigene 
and single gene mutations, we have learned that a mutation in Tbx1, a member of T-box 
family transcription factor gene, is responsible for most of the congenital defects seen in 
patients and mouse models43444546. Rodent models suggest that 22q11.2 deletion leads to 
behavioral changes and deficits in RNA processing. Mice carrying a hemizygous 1.3 
Mb chromosomal deficiency (Df(16)A+/-)22 showed deficits in pre-pulse inhibition 
(PPI), a test of sensory information-processing of external stimuli. PPI deficits are 
frequently observed in several psychiatric and neurological diseases including 
schizophrenia, obsessive-compulsive disorder, ADHD, and Huntington's disease47. In 
addition to PPI deficits, Df(16)A+/- mice showed dysregulation in miRNA biogenesis 27. 
In these mice, a subset of pri-miRNA was up-regulated and a smaller subset of the 
mature form of the miRNAs was down-regulated due to haploinsufficiency of the 
DiGeorge syndrome critical region 8 gene (Dgcr8: also known as Pasha). Because 
Dgcr8 is an essential component of pri-miRNA processing48, haploinsufficiency of this 
gene may affect brain cognitive functions2749 due to dysregulation of critical 
downstream genes involved in neural development. For example, insulin growth factor 
(IGF) is one gene downstream of Dgcr8. Administration of IGF to Dgcr8 KO mice 
rescued hippocampal functions50. Recently, Mukai et al. reported that deletion of the 
22q11 locus zinc finger and Asp-His-His-Cys (DHHC) domain-containing protein 8 
(Zdhhc8) led to changes in axonal growth, dendrite arborization, synaptic connectivity, 
spatial working memory, and prefrontal-hippocampal synchrony51. Behavioral and 
neuronal abnormalities were consistent between Df(16)A+/- and Zdhhc KO mice. This 
interesting consequence gives rise to new insights into post-translational modification of 
proteins related to cognitive function and abnormal brain circuit formation. 
 
2.3. MECP2  
Mutations in the MECP2 gene cause the neurodevelopmental disorder RTT. This 
syndrome is characterized by small head size (microcephaly), gait abnormalities, loss of 
language, breathing disturbances, and poor motor movements with repetitive 
stereotypies. MECP2 is located on region Xq28 of the X chromosome where deletions, 
mutations, and duplications of this gene have been reported52. Classically, RTT has been 
recognized as a girl’s disorder, with symptomatic women having either a MECP2 point 
mutation or deletion. Women with a MECP2 duplication remain healthy, likely due to 
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skewed X inactivation53. In contrast, boys with a MECP2 duplication present with 
clinical features of RTT. For instance, Meins et al. reported on a MECP2 duplication of 
approximately 430 kb in a boy with hypotonia, mental retardation, lack of speech, and 
loss of motor movements53. Other male patients with MECP2 duplications have 
presented with infantile hypotonia, mental retardation, poor speech development, 
recurrent infections, epilepsy, progressive spasticity, developmental regression, and 
ASD52.  
Mecp2 mutant mice are available to elucidate the role of Mecp2 on 
neurological and psychological functions18. Sztainberg et al. generated a Mecp2 
duplication mouse model through conditional Mecp2-overexpression54. These mice 
displayed hypoactivity, anxiety-like behavior, motor abnormalities, and social deficits, 
which are behaviors seen in patients with a MECP2 duplication. Observed deficits were 
recovered by 1) deleting the conditional Mecp2-overexpression allele by using 
tamoxifen-inducible Cre recombination and 2) stereotactic injection of antisense 
oligonucleotides (ASOs) into the right ventricles of the brain, which then hybridized 
with target mRNA to silence Mecp2. These rescue experiments successfully ameliorated 
the abnormal cortical electroencephalography (EEG), molecular, and 
electrophysiological deficits displayed by Mecp2 duplication mice. Since ASOs 
efficiently suppressed Mecp2 gene expression in mouse brains as well as MECP2 
duplication patient-derived lymphoblastoids, it may be a suitable drug candidate for 
MECP2 duplication patients. However, possible off-target effects still need to be 
determined. 
 
3. Intervention during brain development may treat psychiatric symptoms 
Abnormalities arising from a genetic mutation may effectively be recovered by 
intervention at a young age (Table 2). One study suggesting this was performed on 
contactin-associated protein-like 2 (Cntnap2) KO mice55. Cntnap2 is a member of the 
NRXN gene superfamily and encodes a neuronal transmembrane protein that acts as a 
cell adhesion molecule, implicating the protein in neural plasticity. Cntnap2 KO mice 
showed abnormalities similar to patients with a CNTNAP2 mutation56, such as epileptic 
seizures and an abnormal EEG pattern55. Indeed, Cntnap2 is one of the best-replicated 
risk genes for ASD57. It is therefore not surprising that Cntnap2 KO mice display core 
features of ASD, including repetitive behaviors, behavioral inflexibility, and social 
deficits. Social deficits in neurodevelopmental disorders such as schizophrenia and ASD 
have been suggested to also be caused in part by an imbalance in the neurotransmitter 
oxytocin (OXT)585960. OXT treatment of Cntnap2 KO improved social deficits observed 
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in the reciprocal social interaction and three-chamber social interaction tests. 
Interestingly, the recovery of behavioral deficits was dependent upon the age at which 
OXT was administered. Adult mice (6-8 weeks of age) acutely treated with OXT 
showed improvement in social interactions. Similarly, early postnatal mice (7-21 days 
of age) chronically treated with OXT showed improved social interaction up to one 
week after OXT cessation56. It is therefore possible that OXT can be used to treat social 
deficits, particularly when administered early in life.  
Another study suggesting intervention prior to adulthood may better recover 
deficits was performed on protein interacting with C kinase-1 (Pick1) KO mice. Pick1 
is a postsynaptic protein involved in synaptic plasticity and affects AMPAR trafficking. 
Indeed, hippocampal and cerebellar LTD are significantly impaired in Pick1 KO mice, 
likely due to impaired internalization, recycling, or intracellular retention of AMPAR61. 
During development, neonatal Pick1 KO mice have decreased levels of the NMDAR 
co-agonist D-serine in the prefrontal cortex and hippocampus62. As D-serine levels 
recover later in life, one may be able to use Pick1 KO mice as a conditional D-serine 
knockdown model. Interestingly, adult Pick1 KO mice, who have levels of D-serine 
comparable to wild-type mice, exhibited impaired synaptic plasticity and behavioral 
abnormalities including learning and memory, PPI, and cognitive deficits6364. This 
suggests that decreased levels of D-serine during development adversely affect the brain 
during adulthood. To test whether rescuing D-serine levels during development would 
prevent behavioral deficits during adulthood, Pick1 KO mice were treated with D-serine 
during the neonatal development period (P3-P17). In the treated mice, abnormal 
NMDA-elicited firing in prefrontal pyramidal neurons and PPI deficits were rescued in 
adulthood64. Interestingly, these electrophysiological and behavioral deficits were 
rescued only with D-serine treatment of neonates (P3-P17), and not with D-serine 
treatment of adults (P56-P70)64. These results indicate that neonatal NMDAR activation 
seems indispensable for adult psychopathology. 
Behavioral abnormalities of Mecp2 KO mice can also be recovered by 
intervention during brain development with the chronic NMDAR antagonist ketamine19. 
In this study, the authors treated mice at two different time windows in order to identify 
the critical time period to recover physiological abnormalities. Ketamine was 
administered from either 1) before the onset of RTT symptoms (P15) to P55 (40 days 
total administration) or 2) at the onset of RTT symptoms (P30) until P55 (25 days total 
administration). Interestingly, both ketamine treatment starting before the onset of RTT 
symptoms (P15) and at the onset of RTT symptoms (P30) rescued respiratory function, 
visual activity, neuronal evoked and spontaneous activities, and PV 
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immunofluorescence intensity in the visual cortex of Mecp2 KO mice. Pharmacokinetic 
analysis revealed the low dose of ketamine (8 mg/kg) administered was promptly 
absorbed in the brain without any detrimental side effects. Therefore, ketamine 
administration might be a suitable pharmacotherapy for RTT patients. However, 
whether ketamine can recover existing symptoms of RTT adult patients remains to be 
elucidated. 
 Intervention prior to adulthood has also been shown to recover deficits induced 
by oxidative stress. Oxidative stress affects neuronal synapses, myelin, and interneuron 
integrity. It is one of the known causal factors of neurodegenerative disorders65, and 
may also be involved in the development of psychiatric disorders66. Accumulating 
clinical and epidemiological studies suggest an imbalance in genes involved in 
oxidative and redox signaling in patients with psychiatric disorders. Specifically, 
patients show changes in glutathione (GSH), microsomal glutathione S-transferase 1 
(MGST1), superoxide dismutase (SOD), and catalase (CAT). One rodent model of 
oxidative stress is the neonatal ventral hippocampal lesion (NVHL) rat model. This rat 
model develops behavioral, neurochemical and electrophysiological deficits relevant to 
schizophrenia during adolescence6768. Using NVHL rats, Cabungcal et al. assessed 
whether pre-symptomatic oxidative stress can lead to schizophrenic-like symptoms in 
adults. Indeed, they identified increased oxidative stress in the prefrontal cortex (PFC) 
of both P21 (juvenile) and P61 (adult) NVHL rats. In addition, there was decreased PV 
immune-positive neuron in the PFC of P61 rats, which may reflect cortical disinhibition 
that is frequently seen in patients with schizophrenia. Treatment of NVHL rats from P5 
to P50 with the antioxidant N-acetyl-cysteine (NAC), a glutathione precursor, prevented 
the reduction of cortical PV interneruons, electrophysiological changes, and behavioral 
deficits. These findings suggest that the redox pathway may be a potential drug target 
for patients with schizophrenia, particularly when manipulated during brain 
development. 
 
Table 2. Phenotypic rescue by early intervention 
Animal model Drug/main effect Time 
period 
Rescued behavioral 
phenotypes 
Reference 
Cntnap2 KO 
mouse 
Oxytocin 
(Hormone: 
modulate social 
behavior) 
P7-P21 Social behaviors 
(three-chamber test, 
Reciprocal social 
interaction test) 
Penagarikano 
et al. 
(2015)56 
Pick1 KO D-serine P3-P14 Sensory motor Nomura et 
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mouse (Endogenous 
coagonist for 
NMDAR) 
gating (PPI)  al. (2016)64 
Mecp2 KO 
mouse 
Ketamine 
(Non-competitive 
NMDAR 
antagonist) 
P15-P55 
P30-P55 
RTT-like phenotypes 
(hindlimb-clasping, 
apnea episode, visual 
acuity) 
 
Patrizi et al. 
(2016)19 
NVHL rat NAC (N-acetyl 
cysteine: 
Antioxidant) 
P5-P50 Sensory motor 
gating (PPI) 
Cabungcal et 
al. (2014)68 
 
Discussion 
The best way to ultimately elucidate psychopathological conditions in the brain is to use 
samples from human patients. Yet, acquiring brain tissues from living patients is 
impossible, postmortem brain samples are limited, and non-invasive methods to analyze 
brain structure and activities, such as functional magnetic resonance imaging (fMRI) 
and MRI, have limited outcomes. To overcome these hurdles, some scientists have 
turned to induced pluripotent stem cells (iPSCs) and induced neurons (iNs), which are 
derived from patient samples and therefore helpful in understanding the cellular 
dysfunction of patients. Several types of iPSCs have been generated from patients with 
various diseases to be used in disease modeling and drug screening of therapeutics69. 
For example, iPSCs from three independent patients with MECP2 duplication have 
recently been established70. Expression analysis revealed changes in markers for neural 
progenitors, migration, and development of different brain regions. The cellular 
morphology of neurons derived from iPSCs with MECP2 duplication showed that 
synaptogenesis and dendritic complexity were increased compared with controls, 
suggesting hyper-connected neural networks, which are observed in children with 
ASD7172. Furthermore, patient-derived neurons displayed higher numbers of action 
potentials than controls, which may underlie abnormal glutamatergic neurotransmission. 
Deficits observed in MECP2 iPSCs were ameliorated by the administration of the 
histone deacetylase (HDAC) inhibitor, NCH-51. This study reveals the usefulness of 
iPSCs as a disease model, as well as a tool in drug screening at the cellular level. In 
addition to iPSCs, fibroblasts can now be directly converted into either serotonergic, 
glutamatergic, GABAergic, or dopaminergic neurons73, aiding in unraveling how 
specific cellular systems are affected in certain diseases. The recent success of culturing 
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organoids will accelerate human disease modeling. While iPSCs, iNs, and organoids are 
useful tools because they are derived from patients, they are unable to provide a 
complete picture of deficits throughout the brain. 
Rodent models of genetic mutations found in humans with mental illness have 
been useful in understanding complex brain abnormalities. However, it is obvious that 
rodents are vastly different from humans, and therefore rodent disease models may not 
always reflect human pathophysiological conditions. A good example is the mouse 
model of RTT. Although some exceptions have been reported in clinical studies, most 
MECP2 mutations are lethal in males. However, Mecp2 null mutation in male mice is 
not lethal although they die around 10 weeks of age. Similarly, female Mecp2 
heterozygous mice appear normal at a young age although RTT is characterized as early 
neurological regression74. In a mouse model of Fragile X Syndrome (FXS), it was found 
that a mGluR5 antagonist potently ameliorates phenotypic abnormalities7576. When the 
pharmaceutical companies Roche and Novartis went into Phase II trials of the mGluR5 
antagonist, they found no beneficial effect. This is a common theme for many drugs that 
show promise in rodent models, but not in humans. In addition, as psychiatric disorders 
are multifactorial disorders and may be due to changes in many systems throughout the 
body (e.g. brain vs microbiome and immune system), analysis of the whole body seems 
to be essential to understand pathophysiology of psychiatric disorders. Despite 
differences between rodents and humans, animal models are still valuable tools to study 
human diseases because we can study rodents at the system level, within a living 
organism, and assess drugs in different ways in real time, which are all difficult and 
more costly to do in human subjects. 
As we have discussed, human, rodent, and cell culture studies, all have their 
strengths and weaknesses in understanding the mechanism and treatment of genetic 
disorders as it pertains to the brain. Studies combining all tools may therefore result in 
the most promising avenues to follow through to clinical drug trials. One step in this 
direction is exemplified by a study reported by Hao et al. This group applied deep brain 
stimulation (DBS), which is commonly used in the clinical treatment of humans with 
movement disorders such as Parkinson’s and dystonia77, to work on a RTT mouse model. 
Using DBS, the authors successfully rescued neurological and cognitive deficits in the 
RTT mice78. As suggested by this work, combining human studies (postmortem samples, 
iPSCs or iNs, brain imaging) with animal models of human disease may be necessary to 
truly understand multifactorial psychiatric disorders such as ASD and schizophrenia. 
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